Chronic respiratory disease and survival outcomes after extracorporeal membrane oxygenation

Tak Kyu Oh1, Hyoung-Won Cho2, Hun-Taek Lee1 and In-Ae Song1*

Abstract

Background: Quality of life following extracorporeal membrane oxygenation (ECMO) therapy is an important health issue. We aimed to describe the characteristics of patients who developed chronic respiratory disease (CRD) following ECMO therapy, and investigate the association between newly diagnosed post-ECMO CRDs and 5-year all-cause mortality among ECMO survivors.

Methods: We analyzed data from the National Health Insurance Service in South Korea. All adult patients who underwent ECMO therapy in the intensive care unit between 2006 and 2014 were included. ECMO survivors were defined as those who survived for 365 days after ECMO therapy. Chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, lung cancer, lung disease due to external agents, obstructive sleep apnea, and lung tuberculosis were considered as CRDs.

Results: A total of 3055 ECMO survivors were included, and 345 (11.3%) were newly diagnosed with CRDs 365 days after ECMO therapy. The prevalence of asthma was the highest at 6.1% (185). In the multivariate logistic regression, ECMO survivors who underwent ECMO therapy for acute respiratory distress syndrome (ARDS) or respiratory failure had a 2.00-fold increase in post-ECMO CRD (95% confidence interval [CI]: 1.39 to 2.89; \(P < 0.001\)). In the multivariate Cox regression, newly diagnosed post-ECMO CRD was associated with a 1.47-fold (95% CI: 1.17 to 1.86; \(P = 0.001\)) higher 5-year all-cause mortality.

Conclusions: At 12 months after ECMO therapy, 11.3% of ECMO survivors were newly diagnosed with CRDs. Patients who underwent ECMO therapy for ARDS or respiratory failure were associated with a higher incidence of newly diagnosed post-ECMO CRD compared to those who underwent ECMO for other causes. Additionally, post-ECMO CRDs were associated with a higher 5-year all-cause mortality. Our results suggest that ECMO survivors with newly diagnosed post-ECMO CRD might be a high-risk group requiring dedicated interventions.

Keywords: Acute respiratory distress syndrome, Asthma, COPD, Extracorporeal membrane oxygenation, Interstitial lung diseases, Lung cancer

Background

Extracorporeal membrane oxygenation (ECMO) has been used in the intensive care unit (ICU) as a choice of rescue therapy to treat refractory cardiac and/or respiratory failure [1, 2]. The diseases associated with ECMO therapy include heart failure, heart inflammation, intractable arrhythmia, pulmonary hypertension, severe trauma, acute respiratory distress syndrome...
ARDS, and post-cardiac surgery management [3–7]. The use of ECMO therapy has increased in the United States [8, 9], South Korea [10], and Germany [11]. Furthermore, ECMO has been widely applied as a rescue therapy in patients with ARDS or respiratory failure due to coronavirus disease-2019 (COVID-19), globally [12, 13]. Although critically ill patients requiring ECMO therapy showed a high mortality rate of 54% [14], approximately half of the ECMO patients survived until discharge. In addition, in South Korea, the hospital survival rate among critically ill patients who underwent ECMO therapy due to respiratory failure has been improving in recent years [15]. Therefore, the quality of life (QOL) in ECMO survivors has emerged as an important public health issue [16–19]. One of the most important factors that might affect the worsening QOL in ECMO survivors is the decreased pulmonary function after discharge from the hospital. A recent retrospective cohort study reported that there was a 47% reduction in the diffusion capacity of carbon monoxide and 82% of lung parenchymal pathologic changes in 38 ECMO survivors from respiratory failure [19]. Another retrospective study reported that 21 ECMO survivors from ARDS showed lung fibrosis, and minor pulmonary function abnormalities remained common at the 365-day follow-up period [17]. However, another prospective cohort study recently reported that pulmonary function was almost normal in 33 ECMO survivors from ARDS at the 365-day follow-up period [16]. Thus, the worsening QOL in ECMO survivors due to decreased pulmonary function remains controversial, and its impact on long-term mortality has not yet been clarified.

Therefore, we aimed to describe the characteristics of patients who developed CRD following ECMO therapy, and investigate the association between newly diagnosed post-ECMO CRDs and 5-year all-cause mortality among ECMO survivors. We used data regarding disease diagnosis and mortality for the entire national population of South Korea from the National Health Insurance Service (NHIS) database.

**Methods**

**Study design, and ethical concerns**

As a population-based cohort study, the approval of study protocol was exempted by the Institutional Review Board of the Seoul National University Bundang Hospital (approval number: X-2001-586-902) and the Health Insurance Review and Assessment Service. The requirement for informed consent was waived because the study retrospectively analyzed anonymized data.

**Data source: NHIS database in South Korea**

Health records were extracted from the NHIS database for this study. In South Korea, all diagnoses of disease and prescription of drugs and/or procedures should be registered in the NHIS database for patients to receive financial coverage for any treatment charges. The diagnoses of diseases, in the NHIS database, are registered using the International Classification of Diseases 10th revision (ICD-10). Data were extracted by an independent medical record technician (S.Y. Park), who had no conflicts of interest relative to this study, at the NHIS center on April 3, 2020.

**Study population: ECMO survivors**

In this study, we initially screened all adult patients (≥18 years old) who underwent ECMO therapy in the ICU following hospitalization between 2006 and 2014 (9 years). However, patients in whom ECMO therapy was initiated in the operating room and continued in the ICU were also included in this study. Cases of Novalung therapy were not considered as having undergone ECMO. ECMO survivors were defined as those who survived over 365 days after initiation of ECMO therapy. We were unable to classify the type of ECMO therapy such as venoarterial (VA)- or venovenous (VV)-ECMO, because NHIS database did not distinguish the prescription code of VA- and VV-ECMO.

**Exposure variable: CRD**

The following diseases were considered CRDs: chronic obstructive pulmonary disease (COPD, J44), interstitial lung disease (ILD, J84.9), asthma (J45), lung cancer (C34), lung disease due to external agents (J60-J70), obstructive sleep apnea (OSA, G47.33), and lung tuberculosis (TB, A15). Their data were extracted using ICD-10 codes, and information regarding diagnostic tool such as pulmonary function test or chest computed tomography was not used for determining CRDs. Patients who were newly diagnosed within 365 days after initiation of ECMO therapy in ECMO survivors constituted the post-ECMO CRDs group. Patients who were diagnosed with CRDs within 365 days before initiation of ECMO therapy were included in a separate group. Patients who had not been diagnosed with a CRD within 365 days both before and after ECMO therapy constituted the control group. In South Korea, patients who require medication or surgical procedures for COPD, asthma, or lung cancer, should be registered in the NHIS database using ICD-10 codes by a physician to receive financial coverage for treatment.
Study endpoint
The primary endpoint of this study was the 5-year all-cause mortality in ECMO survivors, which was defined as death within 5 years of undergoing ECMO therapy. The dates of death were extracted until December 31, 2019, and survival times were calculated from the date on which ECMO therapy was started to the date of death or December 31, 2019, whichever occurred first. The secondary endpoint of this study was the new development of post-ECMO CRDs, which was evaluated within 365 days from the date of initiation of ECMO therapy.

Confounders
The data on confounders included demographic characteristics (age, sex, and place of residence at the time of ECMO therapy (Seoul, metropolitan city, and other areas), year of ECMO therapy, annual income level at the time of ECMO therapy, underlying disability, pre-ECMO CRD diagnoses, and Charlson comorbidity index. The Charlson comorbidity index was calculated as the sum of the 17 individual underlying diseases in Additional file 1: Table S1; thus, the Charlson comorbidity index ranged from 0 (best) to 27 (worst) in this study [20]. In South Korea, all individuals with disabilities are registered in the NHIS database to receive various benefits from the social welfare system. Disability was assigned one of six severity grades, and we considered two severity groups (1–3, severe disability; and 4–6, mild to moderate disability).

In addition, the length of hospital stays (days), duration of ECMO therapy (days), and annual volume of ECMO therapy were included as confounders. The annual volume of ECMO therapy was calculated as the total number of ECMO cases/9 years to reflect the capability of the ECMO centers, because high-volume ECMO centers are known to improve survival outcomes of ECMO patients [21]. The annual volume of ECMO therapy was divided into four groups (Q1<14, Q2: 15–29, Q3: 30–64, and Q4>64). We classified the ECMO survivors into three groups based on the main diagnosis at ECMO therapy: (1) cardiovascular group (cardiovascular disease, shock, or post-cardiac arrest), (2) respiratory group (ARDS or respiratory failure), and (3) others.

Statistical analysis
The clinicopathological characteristics of the ECMO survivors are presented as means with standard deviations for continuous variables and numbers with percentages for categorical variables. To compare the clinicopathological characteristics between the three groups (control, pre-ECMO CRD, and post-ECMO CRD), one-way ANOVA and Chi-square tests were used for continuous variables and categorical variables, respectively. Next, we constructed a multivariate logistic regression model for the new development of post-ECMO CRDs within 365 days of ECMO therapy. All covariates were included in the multivariate logistic regression model for adjustment, except for pre-ECMO CRDs, which were not included because the pre-ECMO CRD group had been diagnosed and treated for CRD both before and after ECMO therapy. The Hosmer–Lemeshow test was used to test the goodness of fit in the multivariate logistic regression model. We also constructed a multivariate Cox regression model for 5-year all-cause mortality in survivors (model 1). All covariates were included in the multivariate model for adjustment including pre-ECMO CRD, and survival time was set as duration, and death from any cause during 5-year was set as an event in the time-to-event analysis. To examine the impact of individual post-ECMO CRDs (7 types of CRDs), another multivariate Cox regression model (model 2) was constructed to avoid multicollinearity with multivariate model 1. Finally, subgroup analyses according to the main diagnosis at ECMO therapy considering the type of ECMO were performed using multivariate Cox regression modelling. We confirmed that there was no multicollinearity in all multivariate models involving the entire cohort, with a variance inflation factor of <2.0. The results of the Cox regression were presented as hazard ratios (HRs) with 95% confidence intervals (CIs), and log–log plots were used to confirm that the multivariate Cox model was satisfied with the Cox proportional hazard model. The results of the logistic regression models were presented as odds ratios (ORs) with 95% CIs. R software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses, and a P-value < 0.05 was considered statistically significant.

Results
Study population
From 2006 to 2014, 11,196 patients underwent ECMO therapy in 72 hospitals in South Korea. After excluding 981 patients who were aged <18 years, 10,215 adult ECMO patients were screened. Of these patients, 3055 (29.9%) survived for more than 365 days after the initiation of ECMO therapy and were included in the final analysis. Among them, 840 (27.5%) and 345 (11.3%) were assigned to the pre- and post-ECMO CRD groups, respectively. Five-year all-cause mortality occurred in 556 (18.2%) ECMO survivors. Figure 1 shows a flowchart depicting patient selection. The clinicopathological characteristics of the patients are shown in Table 1. The results of the comparison of the clinicopathological characteristics between the three groups (control,
pre-ECMO CRD, and post-ECMO CRD) are shown in Additional file 2: Table S2. The 5-year mortality rate in the post-ECMO CRD group was the highest (28.4%; 98), followed by the pre-ECMO CRD group (21.2%; 178), and the control group (15.0%; 280). In addition, the proportions of the respiratory group in terms of the main diagnosis associated with ECMO therapy were the highest in the post-ECMO CRD group (16.8%; 58), followed by the pre-ECMO CRD group (11.7%; 98) and the control group (6.7%; 125).

**Development of post-ECMO CRD**
The prevalence of pre- and post-ECMO CRDs are shown in Additional file 3: Table S3. In the pre-ECMO CRD group (840, 27.5%), the prevalence of asthma was the highest at 16.9% (516), followed by that of COPD at 8.1% (247), and lung disease due to external agents at 3.5% (106). In the post-ECMO CRD group, the prevalence of asthma was the highest at 6.1% (185), followed by that of COPD at 3.0% (91) and lung disease due to external agents at 2.2% (68). Table 2 shows the results of the multivariate logistic regression model for the development of post-ECMO CRDs among ECMO survivors. Older age (OR: 1.02, 95% CI: 1.01 to 1.03; \(P<0.001\)) and longer duration of ECMO therapy (OR: 1.02, 95% CI: 1.01 to 1.03; \(P<0.001\)) were associated with an increase in post-ECMO CRDs. In addition, the patients in the respiratory group who underwent ECMO therapy due to ARDS or respiratory failure had a 2.00-fold increase in post-ECMO CRD (OR: 2.00, 95% CI: 1.39 to 2.89; \(P<0.001\)), compared to the patients in the cardiovascular group.

**Post-ECMO CRD and five-year all-cause mortality**
Table 3 shows the results of the multivariate Cox regression models for 5-year all-cause mortality among ECMO survivors. In multivariate model 1, post-ECMO CRD was associated with a 1.47-fold (HR: 1.47, 95% CI: 1.17 to 1.86; \(P=0.001\)) higher 5-year all-cause mortality compared with the control group. In the multivariate model 2, post-ECMO asthma and post-ECMO ILD were associated with a 1.54-fold (HR: 1.54, 95% CI: 1.13 to 2.11; \(P=0.007\)) and 2.33-fold (HR: 2.33, 95% CI: 1.05 to 6.40; \(P=0.042\)) higher 5-year all-cause mortality compared with the control group, respectively. Among the covariates in multivariate model 1, pre-ECMO CRD was associated with a 1.25-fold (HR: 1.25, 95% CI: 1.04 to 1.49; \(P=0.019\)) higher 5-year all-cause mortality compared with the control group. Table 4 shows the results of the subgroup analysis according to the main diagnosis at ECMO therapy. Among ECMO survivors who underwent ECMO therapy due to cardiovascular disease, shock, or post-cardiac arrest (cardiovascular group), post-ECMO CRD was associated with a 1.51-fold (HR: 1.51, 95% CI: 1.10 to 2.08; \(P=0.011\)) higher 5-year all-cause mortality compared with the control group.
Discussion
This population-based cohort study showed that 11.3% of patients were newly diagnosed with CRDs within 365 days after ECMO therapy, and asthma and COPD were most common in the post-ECMO CRDs. Older age, severe underlying disability, longer duration of ECMO therapy, and ECMO therapy due to ARDS or respiratory failure were associated with higher incidence of post-ECMO CRDs. Additionally, post-ECMO CRDs were associated with higher 5-year all-cause mortality among ECMO survivors. Our results suggest that QOL might worsen due to the development of CRDs after ECMO therapy, worsening long-term survival. We believe that our results are important because the number of ECMO survivors is bound to increase in the future due to the COVID-19 pandemic [22], and the

Table 1 The clinicopathological characteristics of the patients

| Variable | Number (%) | Mean (SD) |
|----------|------------|-----------|
| Age, year | 53.4 (15.2) |           |
| Sex, male | 2032 (66.5) |           |
| Residence at ECMO treatment | | |
| Capital city (Seoul) | 770 (25.2) | |
| Other metropolitan city | 631 (20.7) | |
| Other area | 1654 (54.1) | |
| Year of ECMO treatment | | |
| 2006 | 114 (3.7) | |
| 2007 | 144 (4.7) | |
| 2008 | 186 (6.1) | |
| 2009 | 223 (7.3) | |
| 2010 | 271 (8.9) | |
| 2011 | 342 (11.2) | |
| 2012 | 439 (14.4) | |
| 2013 | 580 (19.0) | |
| 2014 | 756 (24.7) | |
| Annual income level at ECMO treatment | | |
| Q1 (Lowest) or unknown | 748 (24.5) | |
| Q2 | 535 (17.5) | |
| Q3 | 763 (25.0) | |
| Q4 (Highest) | 1009 (33.0) | |
| Annual case volume of ECMO therapy | | |
| Q1 < 19 | 508 (16.6) | |
| Q2: 19–43 | 735 (24.1) | |
| Q3: 44–102 | 100 (34.4) | |
| Q4 > 102 | 762 (24.9) | |
| Charlson comorbidity index | 2.8 (2.2) | |
| Underlying disability | | |
| Mild to moderate | 464 (15.2) | |
| Severe | 340 (11.1) | |
| Length of hospital stay, day | 24.6 (15.2) | |
| Duration of ECMO therapy, day | 6.2 (10.3) | |
| 5-year all-cause mortality | 556 (18.2) | |
| Main diagnosis at ECMO treatment | | |
| Cardiovascular group | 1930 (63.2) | |
| Respiratory group | 281 (9.2) | |
| Others | 844 (27.6) | |

SD standard deviation, ECMO extracorporeal membrane oxygenation

Table 2 Multivariable logistic regression model for the development of post-ECMO CRDs among ECMO survivors

| Variable | Multivariable model | P-value |
|----------|---------------------|---------|
| Age, year | 1.02 (1.01, 1.03) | < 0.001 |
| Sex, male | 1.00 (0.78, 1.28) | 0.987 |
| Residence at ECMO treatment | | |
| Capital city (Seoul) | 1 | |
| Other metropolitan city | 0.88 (0.62, 1.27) | 0.502 |
| Other area | 1.09 (0.82, 1.46) | 0.546 |
| Year of ECMO treatment | | |
| 2006 | 1 | |
| 2007 | 2.17 (0.92, 5.15) | 0.078 |
| 2008 | 1.26 (0.52, 3.06) | 0.615 |
| 2009 | 1.10 (0.46, 2.67) | 0.826 |
| 2010 | 1.22 (0.53, 2.84) | 0.638 |
| 2011 | 1.58 (0.71, 3.53) | 0.267 |
| 2012 | 1.28 (0.58, 2.86) | 0.539 |
| 2013 | 1.72 (0.79, 3.72) | 0.171 |
| 2014 | 1.81 (0.84, 3.88) | 0.129 |
| Annual income level at ECMO treatment | | |
| Q1 (Lowest) or unknown | 1 | |
| Q2 | 1.29 (0.87, 1.89) | 0.201 |
| Q3 | 1.28 (0.90, 1.82) | 0.174 |
| Q4 (Highest) | 1.88 (1.36, 2.59) | < 0.001 |
| Annual case volume of ECMO therapy | | |
| Q1 < 19 | 1 | |
| Q2: 19–43 | 1.03 (0.75, 1.41) | 0.859 |
| Q3: 44–102 | 0.67 (0.48, 0.93) | 0.017 |
| Q4 > 102 | 0.54 (0.37, 0.79) | 0.002 |
| Charlson comorbidity index, point | 1.05 (0.99, 1.10) | 0.088 |
| Underlying disability | | |
| Mild to moderate | 1.18 (0.84, 1.64) | 0.344 |
| Severe | 1.81 (1.29, 2.53) | 0.001 |
| Duration of ECMO therapy, day | 1.02 (1.01, 1.03) | < 0.001 |
| Length of hospital day, day | 1.00 (0.99, 1.01) | 0.675 |
| Main diagnosis at ECMO therapy | | |
| Cardiovascular group | 1 | |
| Respiratory group | 2.00 (1.39, 2.89) | < 0.001 |
| Others | 1.21 (0.99, 1.01) | 0.675 |

Hosmer Lemeshow test: Chi-square, 4.08, df = 8, P = 0.850
ECMO extracorporeal membrane oxygenation, CRD chronic respiratory disease, OR odds ratio, CI confidence interval
Table 3  Multivariable Cox regression models for year all-cause mortality among ECMO survivors

| Variable                                                                 | Multivariable model | P-value |
|--------------------------------------------------------------------------|---------------------|---------|
| **Multivariable model 1**                                               |                     |         |
| Post-ECMO CRD (vs control)                                               | 1.47 (1.17, 1.86)   | 0.001   |
| **Multivariable model 2**                                               |                     |         |
| Post-ECMO CRD                                                            |                     |         |
| Post-ECMO COPD                                                           | 1.19 (0.80, 1.79)   | 0.391   |
| Post-ECMO Asthma                                                         | 1.54 (1.13, 2.11)   | 0.007   |
| Post-ECMO ILD                                                           | 2.33 (1.05, 6.40)   | 0.042   |
| Post-ECMO Lung cancer                                                    | 2.21 (0.81, 6.03)   | 0.123   |
| Post-ECMO Lung disease due to external agent                            | 1.07 (0.65, 1.77)   | 0.787   |
| Post-ECMO OSA                                                           | 3.60 (0.48, 27.08)  | 0.214   |
| Post-ECMO TB                                                            | 1.29 (0.67, 2.49)   | 0.443   |
| **Other variables in model 1**                                          |                     |         |
| Age, year                                                                | 1.04 (1.04, 1.05)   | < 0.001 |
| Sex, male (vs female)                                                   | 1.18 (0.98, 1.41)   | 0.087   |
| Residence at ECMO treatment                                              |                     |         |
| Capital city (Seoul)                                                    | 1                   |         |
| Other metropolitan city                                                 | 0.85 (0.65, 1.12)   | 0.250   |
| Other area                                                              | 0.95 (0.77, 1.17)   | 0.633   |
| **Year of ECMO treatment**                                              |                     |         |
| 2006                                                                     | 1                   |         |
| 2007                                                                     | 0.70 (0.41, 1.18)   | 0.176   |
| 2008                                                                     | 0.50 (0.30, 0.86)   | 0.012   |
| 2009                                                                     | 0.55 (0.33, 0.92)   | 0.022   |
| 2010                                                                     | 0.82 (0.52, 1.30)   | 0.406   |
| 2011                                                                     | 0.78 (0.50, 1.21)   | 0.266   |
| 2012                                                                     | 0.78 (0.51, 1.20)   | 0.264   |
| 2013                                                                     | 0.56 (0.37, 0.87)   | 0.009   |
| 2014                                                                     | 0.63 (0.42, 0.96)   | 0.030   |
| **Annual income level at ECMO treatment**                                |                     |         |
| Q1 (Lowest)                                                             | 1                   |         |
| Q2                                                                       | 0.94 (0.72, 1.21)   | 0.615   |
| Q3                                                                       | 0.67 (0.52, 0.86)   | 0.001   |
| Q4 (Highest)                                                            | 0.84 (0.67, 1.056)  | 0.120   |
| **Annual case volume of ECMO therapy**                                  |                     |         |
| Q1 < 19                                                                  | 1                   |         |
| Q2: 19–43                                                               | 0.76 (0.58, 0.99)   | 0.039   |
| Q3: 44–102                                                              | 1.11 (0.88, 1.41)   | 0.379   |
| Q4 > 102                                                                | 0.91 (0.69, 1.21)   | 0.525   |
| **Charlson comorbidity index, point**                                    | 1.05 (1.02, 1.09)   | 0.006   |
| Pre-ECMO CRD (vs control)                                               | 1.25 (1.04, 1.49)   | 0.019   |
| **Underlying disability**                                               |                     |         |
| Mild to moderate                                                         | 0.86 (0.67, 1.11)   | 0.251   |
| Severe                                                                   | 1.92 (1.53, 2.41)   | < 0.001 |
| **Length of hospital stay, day**                                        | 1.00 (0.99, 1.01)   | 0.795   |
| **Duration of ECMO therapy, day**                                       | 1.03 (1.02, 1.03)   | < 0.001 |
| **Main diagnosis at ECMO treatment**                                    |                     |         |
| Cardiovascular group                                                    | 1                   |         |
| Respiratory group                                                       | 1.34 (0.97, 1.85)   | 0.076   |
| Others                                                                   | 2.19 (1.78, 2.68)   | < 0.001 |
and edema may lead to alveolar hypoxia, which causes and maintain SIRS through a vicious cycle [26]. Third, the pulmonary capillary blood flow and blood flow through the bronchial arteries were decreased during VA-ECMO therapy, which may result in lung ischemia [27, 28]. Ultimately, these lung injuries during VA-ECMO therapy can cause persisting lung inflammation and fibrosis, and could result in long-term lung dysfunction among survivors of VA-ECMO [23]. In our study, 195/1930 (10.1%) patients in the cardiovascular group were newly diagnosed with CRD within 365-days following ECMO therapy, and it significantly worsened long-term survival in the subgroup analysis (Table 4). Our results are valuable since we report that post-ECMO CRD might also be clinically important among the cardiovascular group. However, the etiology of CRD after VA-ECMO therapy remains controversial, and further studies, in this regard, are warranted.

The findings in our study are based on the diagnostic codes registered by ICD-10 in the NHIS database, and they differed from previous studies [16, 17, 19], which evaluated decreased pulmonary function using diagnostic tests such as computed tomography. Our approach has both merits and disadvantages in evaluating pulmonary function among ECMO survivors. As a merit, we enrolled a relatively large sample size of 3,055 ECMO survivors and followed up their 5-year mortality using a national database. However, as a disadvantage, our study could not include some cases of CRDs, because some patients with CRDs might not visit outpatient clinics for various reasons such as low compliance to treatment, economic burden, and poor accessibility to medical resources. To interpret our results in the context of those presented in other studies [16, 17, 19], these differences in method should be considered.

In this study, respiratory group in terms of main diagnosis at ECMO therapy was associated with the development of post-ECMO CRDs. The respiratory group had a twofold higher odds of post-ECMO CRD development than those in the cardiovascular group. Therefore, our results suggest that pulmonary sequelae were developed in ECMO survivors without pre-ECMO CRDs after ECMO therapy due to ARDS or respiratory failure, as previously reported [17, 19].

A longer duration of ECMO therapy was also associated with a higher incidence of post-ECMO CRDs among survivors, suggesting there might be a dose-dependent effect. Longer duration of ECMO therapy means that the survivors failed early weaning of ECMO. The longer

| Variable | Multivariable model | P-value |
|----------|--------------------|---------|
| Cardiovascular group |                    |         |
| Control   | 1                  |         |
| Post-ECMO CRD | 1.51 (1.10, 2.08) | 0.011   |
| Respiratory group |                |         |
| Control   | 1                  |         |
| Post-ECMO CRD | 1.74 (0.77, 3.94) | 0.185   |
| Others    |                    |         |
| Control   | 1                  |         |
| Post-ECMO CRD | 1.28 (0.94, 1.74) | 0.112   |

ECMO extracorporeal membrane oxygenation, HR hazard ratio, CI confidence interval, CRD chronic respiratory disease.
duration of ECMO therapy has been known to be a risk factor for higher mortality in patients undergoing both VA- and VV-ECMO therapy [15, 29, 30]. For survivors of ECMO, a recent retrospective cohort study showed that a longer duration of ECMO therapy was associated with a lower rate of complete recovery [31]. Another study reported that the usual duration of ECMO in patients with ARDS was 7–10 days, and patients with prolonged duration ECMO (>14 days) were at a higher risk of mortality with irreversible lung injury [29]. In this study, we showed that the prolonged duration of ECMO therapy was a significant risk factor for newly diagnosed CRDs among survivors.

Interestingly, asthma and COPD were the most common among all post-ECMO CRDs. The accurate mechanism of ECMO therapy with new diagnoses of asthma or COPD has not been identified yet. One possible mechanism is the impact of systemic inflammation during ECMO therapy. Lung and systemic inflammation have been known as key factors in the pathogenesis of asthma and COPD [32]. Exposure to the ECMO circuit causes both systemic and lung inflammatory reactions [33]. Thus, the inflammatory reaction might contribute to the new development of asthma and COPD in the post-ECMO period among survivors. However, the information regarding this phenomenon is lacking, and more research is needed to confirm the relationship between ECMO therapy and development of asthma or COPD.

Our study had several limitations. First, some important variables, including body mass index, alcohol abuse, and smoking history, were not included in the analysis because the necessary information was not available in the NHIS database. Second, we defined comorbidities using their ICD-10 codes to calculate the Charlson comorbidity index; however, the ICD-10 codes might not accurately reflect the actual diseases in the study population. Third, we did not distinguish between VA- and VV-ECMO in this study because of the limited prescription codes for ECMO in South Korea. Therefore, information on the difference in the prevalence of CRD between VA- and VV-ECMO was missing in our study. However, we classified the ECMO survivors considering the main diagnosis at ECMO therapy into the cardiovascular group, respiratory group, and other group. In a recent cohort study, patients who underwent ECMO therapy with a primary diagnosis of acute respiratory failure constituted the VV-ECMO group, while patients who underwent ECMO therapy with a primary diagnosis of cardiogenic shock or cardiac arrest constituted the VA-ECMO group [34]. Thus, our classification using main diagnosis at ECMO therapy might provide some important information for readers on the effect of type of ECMO. Fourth, as mentioned above, the diagnosis of CRD was possibly underestimated because not all patients with CRDs were assessed properly. For example, some patients with CRDs might not visit the outpatient clinic for the treatment of CRDs due to mild symptoms or limited access to medical resource utilization, and they could not be included in this study. Fifth, we did not use diagnostic tools such as pulmonary function test or chest computed tomography for determining post-ECMO CRDs. Lastly, we did not assess the cause of 5-year mortality among survivors of ECMO due to the limitations of our data source.

Conclusions
In conclusion, at 12 months after ECMO therapy, 11.3% of ECMO survivors were newly diagnosed with CRDs, and asthma and COPD were the most common. Factors such as old age, disability, longer duration of ECMO therapy, and ECMO therapy due to ARDS or respiratory failure were associated with the development of post-ECMO CRDs. Additionally, post-ECMO CRDs were associated with higher 5-year all-cause mortality among ECMO survivors.

Abbreviations
ARDS: Acute respiratory distress syndrome; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; COVID-19: Coronavirus disease-2019; CRD: Chronic respiratory disease; ECMO: Extracorporeal membrane oxygenation; HR: Hazard ratio; ICD-10: International Classification of Diseases 10th revision; ICU: Intensive care unit; ILD: Interstitial lung disease; NHIS: National Health Insurance Service; OR: Odds ratio; OSA: Obstructive sleep apnea; SIRS: Systemic inflammatory response syndrome; QOL: Quality of life; VA: Venoarterial; VV: Venovenous.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-021-01796-8.

Acknowledgements
None.

Authors’ contributions
TKO and I-AS designed the study, analyzed the data, interpreted the data, drafted the manuscript, H-WC and H-TL interpreted the data. Methodology, and reviewed the manuscript. All authors read and approved the final version of manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
All data will be available upon reasonable request to the corresponding author.
Declarations

Ethics approval and consent to participate
As a population-based cohort study, the study protocol was approved by the Institutional Review Board of the Seoul National University Bundang Hospital (approval number: X-2001-586-002) and the Health Insurance Review and Assessment Service. The requirement for informed consent was waived because the data analyses were performed retrospectively using anonymized data derived from the South Korean NHIS database.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumi-ro, 173, Beon-gil, Bundang-gu, Seongnam 13620, South Korea. 2Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Gumi-ro, 173, Beon-gil, Bundang-gu, Seongnam 13620, South Korea.

Received: 14 April 2021 Accepted: 1 July 2021
Published online: 05 July 2021

References
1. Gattinoni L, Carlesso E, Langer T. Clinical review: extracorporeal membrane oxygenation. Crit Care. 2011;15:243.
2. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, Da Silva D, Zafrañí L, Tirot P, Peber Y, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378:1965–75.
3. Lafc G, Budak AB, Yener AU, Cicek OF. Use of extracorporeal membrane oxygenation in adults. Heart Lung Circ. 2014;23:10–23.
4. Tramm R, Ilc D, Davies AR, Pellegrino VA, Romero L, Hodgson C. Extracorporeal membrane oxygenation for critically ill adults. Cochrane Database Syst Rev. 2015;1:CD010381.
5. Eckman PM, Katz JH, El Banayosy A, Bohula EA, Sun B, van Diepen S. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock: an introduction for the busy clinician. Circulation. 2019;140:2019–37.
6. Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications: a review. JAMA. 2019;322:557–68.
7. Aneman A, Brechtot N, Brodie D, Coleyev F, Fraser J, Gomennis C, McCannery P, Moller-Sorensen PH, Takala J, Valchanov K, Vallely M. Advances in critical care management of patients undergoing cardiac surgery. Intensive Care Med. 2018;44:799–810.
8. McCarthy FH, McDermott KM, Kini V, Gutschel JT, Wald JW, Xie D, Szeto TW, Bermudez CA, Atunr P, Acker MA, Desai ND. Trends in US extracorporeal membrane oxygenation use and outcomes: 2002–2012. Semin Thorac Cardiovasc Surg. 2015;27:81–8.
9. Vallabhajosyula S, Prasad A, Bell MR, Sandhu GS, Eleid MF, Dunlay SM, Schears GJ, Stulak JM, Singh M, Gersh BJ, et al. Extracorporeal membrane oxygenation use in acute myocardial infarction in the United States, 2000 to 2014. Circ Heart Fail. 2012;5:100929.
10. Tay CK, Cho YH, Park J, Yang JH, Chung CR, Sung K, Cho J, Kang D, Park H, Suh GY. Extracorporeal membrane oxygenation in Korea—trends and impact of hospital volume on outcome: analysis of national insurance data 2009–2014. J Crit Care. 2019;49:1–6.
11. Karagiannides C, Brodie D, Strassmann S, Stoelbenn E, Philipp A, Bein T, Muller T, Windisch W. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42:889–96.
12. Yang X, Cai S, Luo Y, Zhu F, Hu M, Zhao Y, Zheng R, Li X, Hu B, Peng Z. Extracorporeal membrane oxygenation for coronavirus disease 2019—induced acute respiratory distress syndrome: a multicenter descriptive study. Crit Care Med. 2020;48:1289–95.
13. Barbaro RP, MacLaren G, Boonstra PS, Ivashynsa TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning J, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020;396:1071–8.
14. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, Patro-ni N, Antonelli M, Pesenti A, Pappalardo F. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15:172–8.
15. Baek MS, Lee SM, Chung CR, Cho WH, Cho YJ, Park S, Koo SM, Jung JS, Park SY, Chang Y, et al. Improvement in the survival rates of extracorporeal membrane oxygenation-supported respiratory failure patients: a multicenter retrospective study in Korean patients. Crit Care. 2019;23:1.
16. Grasselli G, Scaravilli V, Tubiolo D, Russo R, Crimella F, Bichi F, Morlacchi LC, Scotti E, Patrini L, Gattinoni L, et al. Quality of life and lung function in survivors of extracorporeal membrane oxygenation for acute respiratory distress syndrome. Anesthesiology. 2019;130:572–80.
17. Linden VB, Lidegaard MK, Friisen G, Dahlgren P, Frenckner BP, Larsen F. ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and function and health-related quality of life. Acta Anaesthesiol Scand. 2009;53:489–95.
18. Tiedebohl JM, Defabo ME, Bell T, Buchko BL, Woods AB. ECMO survivors' quality of life and needs after discharge: a descriptive, comparative cross-sectional study. Intensive Care Med. 2020;S59:102829.
19. von Bahr V, Kalzen H, Frenckner B, Hultman M, Friisen KG, Lidegaard MK, Diaz S, Malfertheimer MV, Millar JE, Dobrosavljevic T, et al. Long-term pulmonary function and quality of life in adults after extracorporeal membrane oxygenation for respiratory failure. Perfusion. 2019;34:49–57.
20. Sundararajan V, Henderson T, Perry C, Muggavan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94.
21. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, Annich GM. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med. 2015;191:894–901.
22. Biancani F, Mariscalco G, Dalen M, Settembre N, Welp H, Perrotti A, Wiebe K, Leo E, Loforte A, Chocor S, et al. Six-month survival after extracorporeal membrane oxygenation for severe COVID-19. J Cardiothorac Vasc Anesth. 2021. https://doi.org/10.1053/j.jvca.2021.01.027.
23. Roumy A, Liaudet L, Rusca M, Marucci C, Kirsch M. Pulmonary complications associated with veno-arterial extra-coronal membrane oxygenation: a comprehensive review. Crit Care. 2020;24:212.
24. Bhata M, Zemans RL, Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 2012;46:566–72.
25. Ostadal P, Mlicek M, Kruger A, Hala P, Mates M, Vondrakova D, Svoboda T, Hradovna M, Janotchka M, et al. Increasing venoarterial extracorporeal membrane oxygenation flow negatively affects left ventricular performance in a porcine model of cardiogenic shock. J Transl Med. 2015;13:266.
26. Frohlich S, Boylan J, McLoughlin P. Hypoxia-induced inflammation in the lung: a potential therapeutic target in acute lung injury? Am J Respir Cell Mol Biol. 2013;48:271–9.
27. Schlesak C, Doenst T, Preusser S, Wunderlich M, Kleinschmidt M, Beyerdsorf F. Bronchial artery perfusion during cardiopulmonary bypass does not prevent ischemia of the lung in piglets: assessment of bronchial artery blood flow with fluorescent microspheres. Eur J Cardiothorac Surg. 2001;19:326–31; discussion 331-322.
28. Vardi A, Jessen ME, Chao RY, Brink LW, Levin DL, Johnson RL. Effect of extracorporeal membrane oxygenation flow on pulmonary capillary blood flow. Crit Care Med. 1995;23:726–32.
29. Rosenbaum AA, Haft JW, Bartlett R, Ivashyna TJ, Huang SK, Lynch WR, Napolitano LM. Prolonged duration ECMO for ARDS: futility, native lung recovery, or transplantation? ASAIO J. 2013;59:642–50.
30. Staudacher DL, Bode C, Wengnemeyer T. Duration of extracorporeal membrane oxygenation is a poor predictor of hospital survival. J Crit Care. 2016;32:207–8.
31. Yeoh HI, Kim YS, Kim DJ, Committee ER, Cho WH. Risk factors for complete recovery of adults after weaning from veno-venous extracorporeal membrane oxygenation for severe acute respiratory failure: an analysis from
adult patients in the Extracorporeal Life Support Organization registry. J Intensive Care. 2020;8:64.
32. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc. 2009;6:636–47.
33. Millar JE, Fanning JP, McDonald CJ, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20:387.
34. Cheng W, Ma XD, Su LX, He HW, Wang L, Tang B, Du W, Zhou YK, Wang H, Cui N, et al. Cross-sectional study for the clinical application of extracorporeal membrane oxygenation in Mainland China, 2018. Crit Care. 2020;24:554.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.